Financials data is unavailable for this security.
View more
Year on year Marker Therapeutics Inc had revenues fall -5.76% from 3.51m to 3.31m, though the company grew net income from a loss of 29.93m to a smaller loss of 8.24m.
| Gross margin | -- |
|---|---|
| Net profit margin | -178.54% |
| Operating margin | -188.94% |
| Return on assets | -63.39% |
|---|---|
| Return on equity | -79.76% |
| Return on investment | -79.76% |
More ▼
Cash flow in USDView more
In 2023, Marker Therapeutics Inc increased its cash reserves by 28.26%, or 3.33m. Cash Flow from Investing totalled 18.66m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 16.44m for operations while cash generated from financing totalled 1.11m.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.837 |
|---|---|
| Tangible book value per share | 0.837 |
More ▼
Balance sheet in USDView more
| Current ratio | 3.15 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
